Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,002.95 USD
+2.16 (0.22%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1,002.26 -0.69 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,002.95 USD
+2.16 (0.22%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $1,002.26 -0.69 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Zacks News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Health Care Stocks Show Relative Strength as S&P 500 Stalls
by Bryan Hayes
Several stocks are breaking out and trading near all-time highs.
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
by Zacks Equity Research
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate
by Zacks Equity Research
J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.
Regeneron (REGN) Announces Positive Data on Oncology Candidate
by Zacks Equity Research
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
by Zacks Equity Research
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
by Zacks Equity Research
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
by Zacks Equity Research
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
by Zacks Equity Research
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
EXEL vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. REGN: Which Stock Is the Better Value Option?
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
Regeneron (REGN) Reports Next Week: What You Should Expect
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
by Zacks Equity Research
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).